ArticleHuman vaccines & immunotherapeutics2025
Acceptability of patient-centered digital vaccine safety monitoring: A Canadian Immunization Research Network study.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The future of vaccination: Innovations emerging from the COVID-19 pandemic.Human vaccines & immunotherapeutics · 2026Article
- Diphtheria-tetanus-acellular pertussis vaccine safety in children under 7 years: a post-marketing analysis of the U.S. vaccine adverse event reporting system.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the willingness of Canadians to use patient-centered digital reporting solutions for adverse events following immunization (AEFI) reporting. We identified the preferred medium for reporting, and any privacy and confidentiality concerns among prospective users. A geographically diverse panel of 2,036 Canadian adults 18 y of age and older was surveyed online in September 2024. Descriptive statistics and a multivariable regression model were used to identify factors associated with a willingness to report AEFI. Among respondents 85% (n = 1724) indicated a willingness to report AEFI, and most (n = 1137, 56%) preferred to report AEFI only when they occurred as opposed to answering survey on a regular basis for a short duration after vaccination (n = 458, 22%). The largest proportion of respondents (n = 911, 45%) indicated a preference to use an online fillable form through a secure government website to report AEFI. Living with a disability, age over 24 y and having a great deal of confidence in scientists were all significantly associated with a willingness to report, while having a great deal of trust in pharmaceutical companies was inversely associated. Our results emphasize the importance of considering convenience, privacy and confidentiality, and trust in public institutions when developing patient-centered digital reporting systems for AEFI. Future research should explore income and ethnic disparities in willingness to report AEFI and the effect of tailoring reporting systems to public concerns on willingness to report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.